| Cat.No. | Name | Information |
|---|---|---|
| M59211 | Peresolimab | Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis. |
| M59182 | Anzurstobart | Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab. |
| M59172 | PF-03732010 (CHO) | PF-03732010 is a humanized antibody targeting CDH3/P-cadherin. |
| M59147 | Ecromeximab | Ecromeximab (KM 871; KW 2871) is an IgG-κ chimeric antibody targeting ganglioside GD3. |
| M59069 | Depatuxizumab | Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. |
| M59065 | Lifastuzumab | Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. |
| M58975 | ADCT-901 | |
| M58698 | Anti-Mouse CD40 Antibody (Clone FGK45) In vivo | CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors. Clone FGK45 recognizes an epitope on mouse CD40. |
| M58555 | Volociximab | Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). |
| M58432 | Anti-Mouse RANKL/CD254 Antibody (Clone 7C6) In vivo | Anti-Mouse RANKL/CD254 Antibody (Clone 7C6) is a Mouse-derived VHH-mFc type antibody, targeting to mouse RANKL/CD254. |
| M58370 | Gemtuzumab | Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for the synthesis of antibody-drug conjugate (ADC) Gemtuzumab ozogamicin. |
| M55700 | Anti-human CD52 mAb (HEK293) | |
| M55669 | Anti-Mouse IFNß (interferon beta) Antibody (Clone HDß-4A7) In vivo | Anti-Mouse Interferon-beta (IFN-ß) (Clone HDß-4A7) recognizes an epitope on Mouse IFN-ß and binds specifically to murine IFNß and does not bind murine IFNg or several different IFNa species (a-1,4,5 or 13); HDb-4A7 binds both recombinant and natural forms. |
| M55206 | Lintuzumab | Lintuzumab is a humanized monoclonal antibody directed against CD33, which is expressed on the majority of myeloblasts in acute myeloid leukemia. |
| M55043 | Cinpanemab | Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease. |
| M55042 | Cofetuzumab | Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. |
| M55041 | Crizanlizumab | Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs). |
| M54716 | Trontinemab | Trontinemab is a bispecific human IgG1-κ antibody that targets amyloid β A4 precursor protein (APP) and transferrin receptor (TFRC).Trontinemab may be used in Alzheimer's disease-related studies. |
| M54553 | Erfonrilimab | Erfonrilimab is a humanized single-domain bispecific antibody-Fc fusion protein (VH-VH-h-CH2-CH3 dimer) targeting the immune checkpoints PD-L1 and CTLA-4. |
| M54551 | Rademikibart | Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
